Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma

BACKGROUND: Ipilimumab is an approved immunotherapy that has shown an overall survival benefit in patients with cutaneous metastatic melanoma in two phase III trials. As results of registrational trials might not answer all questions regarding safety and efficacy of ipilimumab in patients with advan...

Descripción completa

Detalles Bibliográficos
Autores principales: Zimmer, Lisa, Eigentler, Thomas K., Kiecker, Felix, Simon, Jan, Utikal, Jochen, Mohr, Peter, Berking, Carola, Kämpgen, Eckhart, Dippel, Edgar, Stadler, Rudolf, Hauschild, Axel, Fluck, Michael, Terheyden, Patrick, Rompel, Rainer, Loquai, Carmen, Assi, Zeinab, Garbe, Claus, Schadendorf, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635983/
https://www.ncbi.nlm.nih.gov/pubmed/26541511
http://dx.doi.org/10.1186/s12967-015-0716-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635983/
https://www.ncbi.nlm.nih.gov/pubmed/26541511
http://dx.doi.org/10.1186/s12967-015-0716-5

Ejemplares similares